Amryt Pharma plc

Amryt Pharma plc, a biopharmaceutical company, focuses on developing and delivering various treatments to help improve the lives of patients with rare or orphan diseases. The company operates through two segments, Commercial, and Research and Development. Its commercial products include Lojuxta that is used to treat Homozygous Familial Hypercholesterolaemia, a rare cholesterol disorder; and derma-cosmetic products for the treatment of allergy-prone and dry skin. The company’s products in development comprise AP101 for treating Epidermolysis Bullosa; AP102; and AP103, a disease-modifying therapy for patients with recessive dystrophic epidermolysis bullosa. It operates in European Economic Area and internationally. Amryt Pharma plc is based in London, the United Kingdom.